

Reference:	FOI.11349.23
Subject:	Treatments for any disease
Date of Request:	23 March 2023

Requested:

1. In the past 3 months [latest 3 months available] how many patients have received the following treatments [for any disease]:
Berinert (Human C1-esterase inhibitor)
Cinryze (Human C1-esterase inhibitor)
Orladeyo (berotralstat)
Takhzyro (Lanadelumab)
Ruconest (Recombinant human C1-esterase inhibitor)
Firazyr (Icatibant)
Icatibant – any brand except Firazyr
2. In the past 3 months [latest 3 months available] how many patients have received the following immunoglobulin treatments [for any disease]:
Cutaquig
Cuvitru
Gammanorm
Gammagard
Hizentra
Hyqvia
Intratect
Iqymune
Kiovig
Privigen
Octagam
Panzyga
Subgam
Any other normal immunoglobulin

Response:

1. Hywel Dda University Health Board (UHB) provides, within the table below, the number of patients treated with each of the listed medications, during the period 1 December 2022 to 28 February 2023.

Medication	Number
Berinert (Human C1-esterase inhibitor)	0
Cinryze (Human C1-esterase inhibitor)	0
Orladeyo (berotralstat)	0
Takhzyro (Lanadelumab)	0
Ruconest (Recombinant human C1-esterase inhibitor)	0
Firazyr (Icatibant injection)	0
Icatibant – any brand except Firazyr	0

2. The UHB provides, within the table below, the number of patients treated with each of the listed immunoglobulin medications, during the period 1 December 2022 to 28 February 2023.

Medication	Number
Cutaquig	0
Cuvitru	0
Gammanorm	0
Gammagard	0
Hizentra	0
Hyqvia	0
Intratect	*
Iqymune	*
Kiovig	*
Privigen	64
Octagam	*
Panzyga	0
Subgam	0
Any other normal immunoglobulin	10

Where the figures in the table have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients, due to the low number of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed.

The UHB is therefore withholding this detail under Section 40(2) of the Freedom of information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018 and the UK General Data Protection Regulations (UK GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/UK GDPR define personal data as data which relates to a living individual who can be identified solely from that data, or from that data and other information, which is in the possession of the data controller.